Adverum Announces Shortened Timelines and Clear Development Path for ADVM-022 Intravitreal Gene Therapy in Wet AMD, Reports Recent Business Progress and Fourth Quarter 2020 Financial Results

The Company also reported financial results for the fourth quarter ended December 31, 2020, and provided a business update.